Scryb Inc. Provides Early Warning Update on Holdings in Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) ("Scryb'' or the "Company"), is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer" or "Cybeats"). Scryb's total share ownership position of Cybeats is unchanged following all transactions outlined in this press release. Scryb outlines below that it accepted common shares in lieu of cash repayment from Cybeats Techno
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-01-14 9:08 PM EST | NorthPalm Capital Corp.
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity. PharmaT
Biotechnologies, Pharmaceutique
2026-01-14 8:00 AM EST | PharmaTher Holdings Ltd.
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026. Chief Executive Officer Dane Stevens is scheduled to host virtual one-on-one meetings with institutional invest
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-01-14 7:30 AM EST | Optimi Health Corp.
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026) OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record date OSAH to focus primarily on the re-establishment of USDA conditional approval and commercialization of
2026-01-14 7:00 AM EST | OS Therapies
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Highlights ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment Supports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverage Establishe
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-01-14 2:00 AM EST | TempraMed Technologies Ltd.
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ:
Biotechnologies, Cannabis, Santé, Producteurs de cannabis
2026-01-13 7:27 AM EST | Cardiol Therapeutics Inc.
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each, a "Unit") at a price of $0.76 p
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-01-12 5:30 PM EST | TempraMed Technologies Ltd.
OS Therapies Enters into Warrant Inducement Agreements
New York, New York--(Newsfile Corp. - January 12, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("O
2026-01-12 8:01 AM EST | OS Therapies
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ with or without papillary disease (±Ta/T1). Combination therapy aims to offer a comple
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-01-12 7:00 AM EST | Theralase Technologies Inc.
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding. CBIH confirms receipt of a communication from the Centers for Med
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-01-12 7:00 AM EST | Cannabis Bioscience International Holdings
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce highly promising results from a two-arm phase 1 clinical study of the safety and
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-01-08 8:00 AM EST | BioVaxys Technology Corp.
MustGrow Announces Non-Brokered LIFE Offering of up to $2 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - January 8, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered private placement of up to 4,000,000 units of the Company (each, a "Unit") at a price of $0.50 per Unit for gross proceeds of up to $2,000,000 (the "LIFE Offering"). Each Unit will consist of (i) one common share of the Company (a "Share"); and (ii)
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-01-08 7:00 AM EST | MustGrow Biologics Corp.
BioHarvest Sciences Issues Year End Shareholder Letter
British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel. Dear Fellow Shareholders, 2025 marked an important milestone for BioHarvest Scie
Biotechnologies, Pharmaceutique, Santé
2026-01-07 7:30 AM EST | BioHarvest Sciences Inc.
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial shipment to the warehouse of Guri A.A.O. ("Guri"), a leading Israeli medical distribution company.
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-01-06 5:00 PM EST | TempraMed Technologies Ltd.
Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") has announced it has mined a block on the Bitcoin Cash ("BCH") blockchain using proprietary mining infrastructure operated by the Company. BCH block #931,986 was mined on Jan 1, 2026 with miner ID "MOSS" included in the coinbase signature. This mining activity represents the Company's first operation in the Bitcoin ecosystem. As a team with
2026-01-05 9:29 AM EST | Moss Genomics Inc.
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 31, 2025) acquisition (the "Transaction") of limited partnership units of Canurta Limited Partnership ("Canurta"), the p
Biotechnologies, Cannabis, Psychédéliques, Producteurs de cannabis
2026-01-05 8:00 AM EST | PharmaDrug Inc.
OS Therapies Provides First Half 2026 Corporate Outlook
Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma (Metastatic Osteosarcoma Program) under Accelerated Approval Program Biomarker data from Phase 2b Metastatic Osteosarcoma Program human clinical trial expected to be released during week of J.P. Morgan Healthcare Conference 202
2026-01-05 7:40 AM EST | OS Therapies
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Exe
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-01-05 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd.
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders. Dear Shareholders, With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead
Biotechnologies, Pharmaceutique
2026-01-02 8:00 AM EST | PharmaTher Holdings Ltd.